Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 12, 2013 - Issue 5
Submit an article Journal homepage
1,290
Views
17
CrossRef citations to date
0
Altmetric
Editorial

A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?

George J KontoghiorghesPostgraduate Research Institute, 3, Ammochostou street, Limassol 3021, Cyprus+0035726272076; +0035726271434; [email protected]
Pages 605-609 | Published online: 21 May 2013

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Christina N Kontoghiorghe & George J Kontoghiorghes. (2016) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 10, pages 465-481.
Read now
Ali T Taher, John B Porter, Antonis Kattamis, Vip Viprakasit & M Domenica Cappellini. (2016) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 10, pages 4073-4078.
Read now
Alessandro Riva. (2013) Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?. Expert Opinion on Drug Safety 12:5, pages 793-795.
Read now

Articles from other publishers (14)

George J. Kontoghiorghes. (2023) Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. International Journal of Molecular Sciences 24:23, pages 16749.
Crossref
George J. Kontoghiorghes. (2023) The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases. Pharmaceuticals 16:7, pages 1016.
Crossref
George J. Kontoghiorghes. (2021) Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs. Medicines 8:7, pages 36.
Crossref
Marianna Tosato & Valerio Di Marco. (2019) Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs. Biomolecules 9:7, pages 269.
Crossref
Upendra Bulbake, Alka Singh, Abraham J. Domb & Wahid Khan. (2019) Therapeutic Macromolecular Iron Chelators. Current Medicinal Chemistry 26:2, pages 323-334.
Crossref
Venty Venty, Rismarini Rismarini, Dian Puspitasari, Yudianita Kesuma & Raden Muhammad Indra. (2018) Depression in children with thalassemia major: prevalence and contributing factors. Paediatrica Indonesiana 58:6, pages 263-8.
Crossref
Scott Ayton, Peng Lei, Catriona Mclean, Ashley I Bush & David I Finkelstein. (2016) Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson’s substantia nigra. Signal Transduction and Targeted Therapy 1:1.
Crossref
Christina N Kontoghiorghe & George J Kontoghiorghes. (2016) New developments and controversies in iron metabolism and iron chelation therapy. World Journal of Methodology 6:1, pages 1.
Crossref
Jasmine L Hamilton & Jayachandran N Kizhakkedathu. (2015) Polymeric nanocarriers for the treatment of systemic iron overload. Molecular and Cellular Therapies 3:1.
Crossref
Rodolfo Cançado, Murilo R. Melo, Roberto de Moraes Bastos, Paulo C. J. L. Santos, Elivira M. Guerra-Shinohara, Carlos Chiattone & Samir K. Ballas. (2015) Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study. European Journal of Haematology 95:6, pages 545-550.
Crossref
Joshua P. Gray & Sidhartha D. Ray. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 259 272 .
Tristan Pascart, Pascal Richette & René-Marc Flipo. (2014) Treatment of Nongout Joint Deposition Diseases: An Update. Arthritis 2014, pages 1-8.
Crossref
Christina N Kontoghiorghe. (2014) World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World Journal of Methodology 4:3, pages 163.
Crossref
Joshua P. Gray & Sidhartha D. Ray. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 323 337 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.